"作为首项在肥胖受试者中评估脂肪靶向THRβ激动剂与肠促胰素药物联用的研究，我们非常欣喜地看到 脂肪靶向THRβ激动剂ASC47联用肠促胰素治疗产生了显著的减重协同疗效，减重效果相对提升高达 56.2%，并大幅改善了胃肠道耐受性，"歌礼创始人、董事会主席兼首席执行官吴劲梓博士表示，"这项 研究提供了重要的概念验证数据，将为我们后续的包括肥胖症和代谢相关脂肪性肝炎(MASH)等多种代 谢疾病的IIb期联合用药研究设计提供关键依据。" ASC47-103研究(NCT06972992)是一项在美国开展的随机、双盲、安慰剂对照的研究，旨在评估超长效 皮下注射ASC47单次给药与司美格鲁肽(0.5毫克，每周一次，给药四次)联用对比等量(volume-matched) 安慰剂与司美格鲁肽(0.5毫克，每周一次，给药四次)联用在肥胖受试者中的安全性、耐受性及疗效。治 疗期为4周，随访期为6周。该研究在美国开展，共入组了28例肥胖受试者。研究目标包括安全性、耐受 性、药代动力学、ASC47三种不同剂量单次给药(10毫克、30毫克和60毫克)与司美格鲁肽(0.5毫克，每 周一次，给药四次)联用的减重疗效评估。由于治疗周期短(2 ...

Group 1 - The core finding of the study indicates that the combination of ASC47 and semaglutide resulted in a weight loss effect that was enhanced by up to 56.2% compared to the placebo and semaglutide combination [1][2] - The ASC47-103 study was a randomized, double-blind, placebo-controlled trial conducted in the United States, involving 28 obese participants with a body mass index (BMI) of 30 kg/m² or higher [1] - The study aimed to evaluate the safety, tolerability, and efficacy of a single dose of ASC47 in three different dosages (10 mg, 30 mg, and 60 mg) in conjunction with semaglutide, with a treatment period of 4 weeks and a follow-up period of 6 weeks [1] Group 2 - The CEO of the company expressed satisfaction with the significant synergistic weight loss effects observed from the combination of the fat-targeting THRβ agonist ASC47 and the incretin therapy, which also greatly improved gastrointestinal tolerability [2] - This study serves as an important proof-of-concept and will provide critical data for the design of subsequent Phase IIb combination therapy studies targeting obesity and metabolic-associated fatty liver disease (MASH) [2]

Core Viewpoint - The study indicates that the combination of ASC47 and semaglutide significantly enhances weight loss in obese subjects compared to semaglutide alone, with a relative improvement of up to 56.2% [1] Group 1: Drug Efficacy - ASC47, a fat-targeting THRβ agonist, when combined with the gut hormone drug semaglutide, shows a significant synergistic effect on weight loss in obese participants (BMI ≥ 30 kg/m²) [1] - The combination therapy not only improves weight loss outcomes but also significantly enhances gastrointestinal tolerability [1] Group 2: Future Research Implications - The results provide important concept validation data that will inform the design of subsequent Phase IIb combination therapy studies for various metabolic diseases, including obesity and metabolic-associated fatty liver disease (MASH) [1]